Treg cells in the tumor microenvironment are expected to be potential biomarkers for PD-1 blockade therapy, as they help regulate the immune response in tumors [31]. Real-time therapeutic monitoring is essential for predicting lung cancer immunotherapy outcomes. Moreover, genetic mutations can impact the therapeutic efficacy of PD-1/PD-L1 inhibitors. The gene discussed is CD274; the disease is lung carcinoma.